William Simpson
Family · Chickamauga, GANPI 1437574134
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,975 of the $29,181 with a category attached, or 65.0%. AbbVie accounts for 85.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $24,336 and has fallen 94.9% since, to $1,235 in 2025. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $119.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- AstraZeneca$1K
- Intuitive Surgical$737
- Sanofi-aventis U.S. LLC$318
- Novo Nordisk$304
- Lilly USA, LLC$279
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$18,97565%
- Travel & lodging$5,14918%
- Food & beverage$5,05717%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 116 | $24,894 |
| AstraZeneca | 20 | $1,029 |
| Intuitive Surgical | 2 | $737 |
| Sanofi-aventis U.S. LLC | 14 | $318 |
| Novo Nordisk | 11 | $304 |
| Lilly USA, LLC | 13 | $279 |
| Pfizer | 10 | $219 |
| Phathom Pharmaceuticals, Inc. | 5 | $171 |
| Xeris Pharmaceuticals, Inc. | 9 | $166 |
| Amgen | 5 | $162 |
| Lundbeck LLC | 5 | $134 |
| GSK | 2 | $111 |
| Mylan Specialty L.p. | 4 | $96 |
| Medtronic | 2 | $65 |
| Shield Therapeutics Inc | 3 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Antares Pharma, Inc. | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Exact Sciences | 2 | $32 |
| Insulet Corporation | 2 | $30 |
| Harmony Biosciences LLC | 1 | $29 |
| Saluda Medical Americas, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $17 |
| Genentech USA, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$23,476
- Da Vinci Surgical System$718
- BREZTRI$246
- FARXIGA$125
- Ozempic$123
- SOLIQUA 100/33$122
- AIRSUPRA$107
How this compares
$29,181 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $122,416 |
| FarxigaDapagliflozin Propanediol | 108 | $121,646 |
| MounjaroTirzepatide | 62 | $77,574 |
| OzempicSemaglutide | 52 | $67,526 |
| JardianceEmpagliflozin | 46 | $57,276 |
| TrulicityDulaglutide | 25 | $41,956 |
| JanuviaSitagliptin Phosphate | 27 | $41,117 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $36,952 |
| VraylarCariprazine Hcl | 20 | $30,086 |
| RybelsusSemaglutide | 14 | $24,115 |
| XareltoRivaroxaban | 12 | $15,802 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $14,375 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,643 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $7,717 |
| Spiriva HandihalerTiotropium Bromide | 15 | $7,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,029 | $136,021124 claims |
| PfizerEliquis, Premarin | $219 | $127,171116 claims |
| Lilly USA, LLCMounjaro, Trulicity | $279 | $119,53087 claims |
| Novo NordiskOzempic, Rybelsus | $304 | $91,64166 claims |
| GSKTrelegy Ellipta | $111 | $36,95240 claims |
| AbbVieVraylar, Synthroid | $24,894 | $32,36639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Chickamauga
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
- Julia ThorneCanton$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.